We are dedicated to the development of our proprietary novel cancer immunotherapy products. Currently, our leading product candidate targets hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). We are actively extending our proprietary TCR therapy platform to target more viruses, particularly those prevalent in Asia.
Contact email@example.com for more information.
Phase 1 50%
Targeting HCC recurrence
HCC recurrence is a common problem following liver transplantation or surgical resection in patients with HCC. Our TCR-T cells are currently in phase 1 trials for their use as a prophylaxis (LTCR-H1-1) or treatment (LTCR-H1-2, LTCR-H1-3) for recurrent HCC.
We are developing our TCR-T cells for additional indications in viral infection and viral-related cancers. We have in pre-clinical development TCR-T cells for treatment of chronic HBV infection (LTCR-H2-1), and Epstein-Barr virus (EBV)-related nasopharyngeal carcinoma and post-transplant lymphoproliferative disorders (LTCR-N1-1, LTCR-O1-1).